Engineered Viral Vectors With Targeted Envelope Proteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing viral particles or viral vectors for therapeutic delivery suffer from off-target effects and reduced targeting efficiency, necessitating the development of engineered viral vectors with improved specificity and reduced adverse effects.
Innovation Solution
Engineering viral vectors with modified envelope proteins, including targeting moieties and specific modifications in the E2 domain, such as IgG-binding domains and protease cleavage sites, to enhance transduction efficiency and specificity to target cells, particularly cancer cells and immune cells, by utilizing recombinant envelope proteins derived from viruses like Sindbis and incorporating antibody fragments for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors are used for therapeutic delivery, then therapeutic delivery capability is achieved, but off-target effects and reduced targeting efficiency occur
Solution Approach 1:
The envelope protein is modified with specific targeting moieties at localized regions (such as the E2 domain) to create targeted binding capability while maintaining the overall viral vector structure. This localized modification enables specific recognition of target cells without affecting other regions of the virus
Solution Approach 2:
Targeting moieties act as intermediary components that mediate the interaction between the viral vector and target cells. These moieties serve as the connecting element that enables specific binding to target cell surface receptors, thereby improving targeting efficiency and reducing off-target effects
2Productivity
If envelope protein modifications are added to improve targeting, then transduction efficiency increases, but device complexity increases
Solution Approach 1:
The envelope protein is constructed as a composite structure combining the native viral envelope protein with added targeting moieties. This composite approach allows the viral vector to retain its natural infectivity while gaining targeted binding capability through the integrated targeting components
Solution Approach 2:
The modified envelope protein serves multiple functions simultaneously: it maintains the viral vector's ability to infect cells while also providing specific targeting capability through the incorporated targeting moieties. This multi-functionality is achieved by integrating both viral and targeting functions into a single envelope protein structure
Data Source
AI summary
Described herein are compositions and methods for therapeutic delivery using an engineered viral vector. The engineered viral vector provided herein can improve therapeutic delivery, increase targeting efficiency, and decrease off-targeting or adverse effects.